Education

M.D., University of Missouri, Columbia, 1992

Current position

Professor, Departments of Medicine, Division Infectious Diseases and Medical Microbiology and Immunology

Head Division of Infectious Diseases

Fellowship Program Director Infectious Diseases

University of Wisconsin and William S Middleton VA Hospital

Publications (since 2008)

1. Palmer, J. M., Bok, J. W., Lee, S., Dagenais, T. R., Andes, D. R., Kontoyiannis, D. P. and Keller, N. P. (2013). Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus. PeerJ 1: e4.
   
2. Craig, W. A. and Andes, D. R. (2013). In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57(4): 1577-1582.
   
3. Lepak, A. J., Marchillo, K., Vanhecker, J. and Andes, D. R. (2013). Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 57(1): 579-585.
   
4. Lee, D. G., Murakami, Y., Andes, D. R. and Craig, W. A. (2013). Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother 57(3): 1434-1441.
   
5. Boehme, A.K., McGwin, G., Andes, D., Lyon, G.M., Chiller, T., Pappas, P.G., Baddley, J.W. Race and Invasive Fungal Infection in Solid Organ Transplant Recipients. Submitted
   
6. Connolly, L.A., Riccombeni, A., Lynch, D.B., Holland, L.M., Andes, D., Butler, G. The APSES transcription factor Efg1 regulates a novel phenotype switch in Candida parapsilosis. Submitted
   
7. Mahanty, S., Thomas, E., Naik, S., Lee, K., Andes, D., Gow, N., Panwar, S. Tolerance to cell wall damaging agents is affected by RTA2, a downstream effector of the calcineurin pathway in Candida albicans. Submitted
   
8. Andes, D. (2013). Optimizing antifungal choice and administration. Curr Med Res Opin 29 Suppl 4: 13-18.
   
9. Bulik, C.C., Okusanya, O.O., Bhavnani, S.M., Lepak, A., Forrest, A., Ambrose, P.G., Hoover, J.L., Andes, D.R. Evaluation of the Pharmacokinetics-Pharmacodynamics of GSK2251052 against Gram-Negative Bacilli in a Murine-Thigh Infection Model. Submitted
   
10. Desai, J. V., Bruno, V. M., Ganguly, S., Stamper, R. J., Mitchell, K. F., Solis, N., Hill, E. M., Xu, W., Filler, S. G., Andes, D. R., Fanning, S., Lanni, F. and Mitchell, A. P. (2013). Regulatory role of glycerol in Candida albicans biofilm formation. MBio 4(2): e00637-00612.
    
11. Ng, J.K., Schulz, L.T., Rose, W.E., Fox, B.C., Andes, D.R., Fish, J.T. Daptomycin dosing based on ideal body weight vs. actual body weight: comparison of clinical outcomes. Submitted
    
12. Green, J.V., Orsborn, K.I., Long, J.L., Zhang, M., Tan, Q., Greis, K.D., Porollo, A., Andes, D.R., Hostetter, M.K. Interactions of Candida albicans with Heparin. Submitted
    
13. Mitchell, K. F., Taff, H. T., Cuevas, M. A., Reinicke, E. L., Sanchez, H. and Andes, D. R. (2013). Role of matrix beta-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother 57(4): 1918-1920.
    
14. Assi, M., Martin, S., Wheat, L.J., Hage, C., Freifeld, A., Avery, R., Baddley, J., Vergidis, P., Miller, R., Andes, D., Young, J., Hammoud, K., Huprikar, S., McKinsey, D., Myint, T., Garcia-Diaz, J., Esguerra, E., Kwak, E.J., Morris, M., Mullane, K., Prakash, V., Burdette, J., Sandid, M., Kubrin, J., Kwak, E., Ostrander, D., Kaul, D.R. Histoplasmosis after solid organ transplantation. Submitted
    
15. Zhang, J., Ponomareva, L.V., Marchillo, K., Zhou, M., Andes, D., Thorson, J.S. Doxycycline neoglycorandomization as a model to assess the impact of tetracycline differential glycosylation. Submitted
    
16. Taff, H.T., Mitchell, K.F., Edward, J.A., Andes, D. Genetic basis for Candida biofilm resistance. Future Microbiology. In press
    
17. Lewis, J.S., Lepak, A.J., Thompson, G.R., Craig, W.A., Andes, D.R., Sabol-Dzintars, K.E., JH, Jorgensen. Failure of Clindamycin to Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections. Submitted
    
18. Tebbets, B., Stewart, D., Lawry, S., Nett, J., Nantel, A., Andes, D. and Klein, B. S. (2012). Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay. PLoS ONE 7(5): e36021.
    
19. Andes, D. and Lepak, A. (2012). Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time. Clin Infect Dis 55(3): 391-393.
    
20. Andes, D., Safdar, N., Baddley. J., Kullberg, B.J., Pappas. P. Reply to letter. Clin Infect Dis. 2012; Jun 18 PMID: 22711068
    
21. Rose, W. E., Schulz, L. T., Andes, D., Striker, R., Berti, A. D., Hutson, P. R. and Shukla, S. K. (2012). Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56(10): 5296-5302.
    
22. Nett, J. E., Marchillo, K. and Andes, D. R. (2012). Modeling of fungal biofilms using a rat central vein catheter. Methods Mol Biol 845: 547-556.
    
23. Baddley, J. W., Andes, D. R., Marr, K. A., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Schuster, M. G., Brizendine, K. D., Patterson, T. F., Lyon, G. M., Boeckh, M., Oster, R. A., Chiller, T. and Pappas, P. G. (2013). Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol 51(2): 128-135.
    
24. Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., Hamaker, J., Mitchell, A. P. and Andes, D. R. (2012). A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog 8(8): e1002848.
    
25. Lepak, A. J., Marchillo, K., Pichereau, S., Craig, W. A. and Andes, D. R. (2012). Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 56(11): 5916-5922.
    
26. Lepak, A., Castanheira, M., Diekema, D., Pfaller, M. and Andes, D. (2012). Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother 56(11): 5875-5882.
    
27. Peltier-Pain, P., Marchillo, K., Zhou, M., Andes, D. R. and Thorson, J. S. (2012). Natural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylation. Org Lett 14(19): 5086-5089.
    
28. Dhingra, S., Andes, D. and Calvo, A. M. (2012). VeA regulates conidiation, gliotoxin production, and protease activity in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot Cell 11(12): 1531-1543.
    
29. Finkel, J. S., Xu, W., Huang, D., Hill, E. M., Desai, J. V., Woolford, C. A., Nett, J. E., Taff, H., Norice, C. T., Andes, D. R., Lanni, F. and Mitchell, A. P. (2012). Portrait of Candida albicans adherence regulators. PLoS Pathog 8(2): e1002525.
    
30. Nobile, C. J., Fox, E. P., Nett, J. E., Sorrells, T. R., Mitrovich, Q. M., Hernday, A. D., Tuch, B. B., Andes, D. R. and Johnson, A. D. (2012). A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148(1-2): 126-138.
    
31. Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G. and Kullberg, B. J. (2012). Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54(8): 1110-1122.
    
32. Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., Johnson, E. M., Knapp, C. C., Motyl, M. R., Ostrosky-Zeichner, L. and Walsh, T. J. (2011). Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 70(3): 330-343.
    
33. Andes, D., Ambrose, P. G., Hammel, J. P., Van Wart, S. A., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L. and Bhavnani, S. M. (2011). Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother 55(5): 2113-2121.
    
34. Zeitlinger, M. A., Derendorf, H., Mouton, J. W., Cars, O., Craig, W. A., Andes, D. and Theuretzbacher, U. (2011). Protein binding: do we ever learn? Antimicrob Agents Chemother 55(7): 3067-3074.
    
35. Nett, J. E., Cain, M. T., Crawford, K. and Andes, D. R. (2011). Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J Clin Microbiol 49(4): 1426-1433.
    
36. Taff, H. T., Nett, J. E. and Andes, D. R. (2012). Comparative analysis of Candida biofilm quantitation assays. Med Mycol 50(2): 214-218.
    
37. Nett, J. E., Sanchez, H., Cain, M. T., Ross, K. M. and Andes, D. R. (2011). Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot Cell 10(12): 1660-1669.
    
38. Lockhart, S. R., Wagner, D., Iqbal, N., Pappas, P. G., Andes, D. R., Kauffman, C. A., Brumble, L. M., Hadley, S., Walker, R., Ito, J. I., Baddley, J. W., Chiller, T. and Park, B. J. (2011). Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol 49(7): 2404-2410.
    
39. Chen, Y. L., Brand, A., Morrison, E. L., Silao, F. G., Bigol, U. G., Malbas, F. F., Jr., Nett, J. E., Andes, D. R., Solis, N. V., Filler, S. G., Averette, A. and Heitman, J. (2011). Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell 10(6): 803-819.
    
40. Lockhart, S. R., Zimbeck, A. J., Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Pappas, P. G. and Chiller, T. (2011). In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother 55(8): 3944-3946.
    
41. Lepak, A. J. and Andes, D. R. (2011). Antifungal PK/PD considerations in fungal pulmonary infections. Semin Respir Crit Care Med 32(6): 783-794.
    
42. Finkel, J. S., Yudanin, N., Nett, J. E., Andes, D. R. and Mitchell, A. P. (2011). Application of the systematic "DAmP" approach to create a partially defective C. albicans mutant. Fungal Genet Biol 48(11): 1056-1061.
    
43. Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D. and Cowen, L. E. (2011). Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 7(9): e1002257.
    
44. Ding, C., Vidanes, G. M., Maguire, S. L., Guida, A., Synnott, J. M., Andes, D. R. and Butler, G. (2011). Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans. PLoS ONE 6(12): e28151.
    
45. Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., Hadley, S., Herwaldt, L., Ito, J. I., Kauffman, C. A., Lyon, G. M., Marr, K. A., Morrison, V. A., Papanicolaou, G., Patterson, T. F., Perl, T. M., Schuster, M. G., Walker, R., Wingard, J. R., Walsh, T. J. and Kontoyiannis, D. P. (2011). Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 17(10): 1855-1864.
    
46. Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. and Perlin, D. S. (2011). Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14(3): 164-176.
    
47. Chaturvedi, V., Ramani, R., Andes, D., Diekema, D. J., Pfaller, M. A., Ghannoum, M. A., Knapp, C., Lockhart, S. R., Ostrosky-Zeichner, L., Walsh, T. J., Marchillo, K., Messer, S., Welshenbaugh, A. R., Bastulli, C., Iqbal, N., Paetznick, V. L., Rodriguez, J. and Sein, T. (2011). Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother 55(4): 1543-1548.
    
48. Lepak, A. and Andes, D. (2011). Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin 27(1): 123-147.
    
49. Safdar, N., Smith, J., Knasinski, V., Sherkow, C., Herrforth, C., Knechtle, S. and Andes, D. (2010). Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis 66(1): 7-15.
    
50. Manosuthi, W., Chetchotisakd, P., Nolen, T. L., Wallace, D., Sungkanuparph, S., Anekthananon, T., Supparatpinyo, K., Pappas, P. G., Larsen, R. A., Filler, S. G. and Andes, D. (2010). Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. HIV Med 11(4): 276-281.
    
51. Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., Hadley, S., Herwaldt, L. A., Kauffman, C. A., Knapp, K., Lyon, G. M., Morrison, V. A., Papanicolaou, G., Patterson, T. F., Perl, T. M., Schuster, M. G., Walker, R., Wannemuehler, K. A., Wingard, J. R., Chiller, T. M. and Pappas, P. G. (2010). Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8): 1091-1100.
    
52. Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., Kontoyiannis, D. P., Lyon, G. M., Marr, K. A., Morrison, V. A., Park, B. J., Patterson, T. F., Perl, T. M., Oster, R. A., Schuster, M. G., Walker, R., Walsh, T. J., Wannemuehler, K. A. and Chiller, T. M. (2010). Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8): 1101-1111.
    
53. Okusanya, O.O., Forrest, A., Bhavnani, S.M., Fernandes, P., Ambrose, P.G., Andes D. Pharmacokinetic-Pharmacodynamic Evaluation of CEM 101 Against Streptococcus pneumoniae Using Data from a Murine-Pneumonia Infection Model
    
54. Yu, Z., Smanski, M. J., Peterson, R. M., Marchillo, K., Andes, D., Rajski, S. R. and Shen, B. (2010). Engineering of Streptomyces platensis MA7339 for overproduction of platencin and congeners. Org Lett 12(8): 1744-1747.
    
55. Nett, J. E., Marchillo, K., Spiegel, C. A. and Andes, D. R. (2010). Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun 78(9): 3650-3659.
    
56. Nett, J. E., Sanchez, H., Cain, M. T. and Andes, D. R. (2010). Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202(1): 171-175.
    
57. Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K. and Lepak, A. (2010). In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54(6): 2497-2506.
    
58. Nett, J. E., Crawford, K., Marchillo, K. and Andes, D. R. (2010). Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 54(8): 3505-3508.
    
59. Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., Wingard, J. R., Patterson, T. F., Ito, J. I., Williams, O. D., Chiller, T. and Pappas, P. G. (2010). Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50(12): 1559-1567.
    
60. Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A. and Sheehan, D. (2010). Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13(6): 180-195.
    
61. Freifeld, A. G., Bariola, J. R. and Andes, D. (2010). The role of second-generation antifungal triazoles for treatment of the endemic mycoses. Curr Infect Dis Rep 12(6): 471-478.
    
62. Craig, W. A., Andes, D. R. and Stamstad, T. (2010). In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob Agents Chemother 54(12): 5092-5098.
    
63. Nett, J. E., Lepak, A. J., Marchillo, K. and Andes, D. R. (2009). Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis 200(2): 307-313.
    
64. Andes, D., Pascual, A. and Marchetti, O. (2009). Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53(1): 24-34.
    
65. Nobile, C. J., Nett, J. E., Hernday, A. D., Homann, O. R., Deneault, J. S., Nantel, A., Andes, D. R., Johnson, A. D. and Mitchell, A. P. (2009). Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 7(6): e1000133.
    
66. Van Wart, S. A., Andes, D. R., Ambrose, P. G. and Bhavnani, S. M. (2009). Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 63(4): 409-414.
    
67. Freifeld, A., Proia, L., Andes, D., Baddour, L. M., Blair, J., Spellberg, B., Arnold, S., Lentnek, A. and Wheat, L. J. (2009). Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 53(4): 1648-1651.
    
68. Spellberg, B., Andes, D., Perez, M., Anglim, A., Bonilla, H., Mathisen, G. E., Walsh, T. J. and Ibrahim, A. S. (2009). Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 53(7): 3122-3125.
    
69. Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., Johnson, E. M., Knapp, C. C., Motyl, M. R., Ostrosky-Zeichner, L., Sheehan, D. J. and Walsh, T. J. (2009). Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 47(10): 3142-3146.
    
70. Andes, D., Craig, W., Nielsen, L. A. and Kristensen, H. H. (2009). In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother 53(7): 3003-3009.
    
71. Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Jr., Calandra, T. F., Edwards, J. E., Jr., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L., Reboli, A. C., Rex, J. H., Walsh, T. J. and Sobel, J. D. (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5): 503-535.
    
72. Lee, I., Oh, J. H., Shwab, E. K., Dagenais, T. R., Andes, D. and Keller, N. P. (2009). HdaA, a class 2 histone deacetylase of Aspergillus fumigatus, affects germination and secondary metabolite production. Fungal Genet Biol 46(10): 782-790.
    
73. Balajee, S. A., Kano, R., Baddley, J. W., Moser, S. A., Marr, K. A., Alexander, B. D., Andes, D., Kontoyiannis, D. P., Perrone, G., Peterson, S., Brandt, M. E., Pappas, P. G. and Chiller, T. (2009). Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47(10): 3138-3141.
    
74. Hsu, J., Andes, D. R., Knasinski, V., Pirsch, J. and Safdar, N. (2009). Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients. Eur J Clin Microbiol Infect Dis 28(11): 1343-1351.
    
75. Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G. and Moser, S. A. (2009). Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47(10): 3271-3275.
    
76. LaPlante, K. L., Leonard, S. N., Andes, D. R., Craig, W. A. and Rybak, M. J. (2008). Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 52(6): 2156-2162.
    
77. Lepak, A., Andes, D. (2008). Pharmacodynamics of Antifungal Drugs: A Strategy to Optimize Efficacy. Current Fungal Infection Reports.
    
78. Smith, J. and Andes, D. (2008). Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 30(2): 167-172.
    
79. Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J. and Hou, J. (2008). In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52(2): 539-550.
    
80. Uppuluri, P., Nett, J., Heitman, J. and Andes, D. (2008). Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52(3): 1127-1132.
    
81. Nett, J. E., Guite, K. M., Ringeisen, A., Holoyda, K. A. and Andes, D. R. (2008). Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob Agents Chemother 52(9): 3411-3413.
    
82. Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A. and Andes, D. R. (2008). Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 52(9): 3022-3028.
    
83. Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K. and Bohrmueller, J. (2008). In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52(10): 3497-3503.
    
84. Ostrosky-Zeichner, L., Rex, J. H., Pfaller, M. A., Diekema, D. J., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J. and Walsh, T. J. (2008). Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother 52(11): 4175-4177.
    
85. Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J. and Walsh, T. J. (2008). Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46(8): 2620-2629.
    
86. Vakil, R., Knilans, K., Andes, D. and Kwon, G. S. (2008). Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Pharm Res 25(9): 2056-2064
    
87. Nobile, C. J., Schneider, H. A., Nett, J. E., Sheppard, D. C., Filler, S. G., Andes, D. R. and Mitchell, A. P. (2008). Complementary adhesin function in C. albicans biofilm formation. Curr Biol 18(14): 1017-1024.
    
88. Dagenais, T. R., Chung, D., Giles, S. S., Hull, C. M., Andes, D. and Keller, N. P. (2008). Defects in conidiophore development and conidium-macrophage interactions in a dioxygenase mutant of Aspergillus fumigatus. Infect Immun 76(7): 3214-3220.
    
89. Craig, W. A. and Andes, D. R. (2008). In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother 52(10): 3492-3496.
    
90. Squire, M. W., Ludwig, B. J., Thompson, J. R., Jagodzinski, J., Hall, D. and Andes, D. (2008). Premixed antibiotic bone cement: an in vitro comparison of antimicrobial efficacy. J Arthroplasty 23(6 Suppl 1): 110-114.